Large American pharmaceutical shares rise as the street reacts to Trump’s rate on drugs

Shares of a few large drug makers went beyond wider indexes on Friday when Wall Street started to select President Donald Trump’s last rate announcement.

Shares of Merck, Lilly and J&J all rose less than 1% in the afternoon trade on Friday, slightly higher than the S&P 500 index.

The president said at the end of Thursday that he would place 100% import tax on branded or patented medicines from 1 October, but those rates would not apply to companies that build the American factories. He defined that as “breaking soil” or “under construction”.

Various large drug makers such as Merck & Co. Inc., Eli Lilly and Co. And Johnson & Johnson have announced American expansion plans.

Trump has spoken about pharmaceutical rates for months, but he said that he would slow them down for a year and a half to give companies the time to hit medicines and shift production.

Analysts have said that companies started medicines in the US earlier this year in the US. Jefferies analyst Akash Tewari said in a research memorandum that Thursday’s announcement should not have a material impact on the big drug makers, given their building plans. Fire name pharmaceutical companies also have thick profit margins that can offer some flexibility to make investments and absorb tariff costs. Manufacturers of cheaper generic medicines, which were not mentioned in the announcement of Thursday, not. Generics take into account most American recipes.

David Risinger from Leerink Partners said that smaller drug makers might be vulnerable to the new taxes, although he noticed that it was difficult to predict which.

He said that various questions remain unanswered after the announcement on Thursday. That include whether the action will survive legal challenges and how the sentences “breaking land” and “under construction” are defined for rate enforcement.

Risinger also wondered whether the new taxes could be a negotiating tactic that is linked to an investigation that the administration started in the spring on how importing medicines and their ingredients influences national security.